Teladoc Health Inc. (TDOC)
Teladoc (TDOC) Stock Sinks As Market Gains: Here's Why
Teladoc (TDOC) reachead $8.41 at the closing of the latest trading day, reflecting a -0.71% change compared to its last close.
Why Teladoc Stock Popped by Nearly 12% on Tuesday
An analyst raised his price target on the telehealth leader. The 25% increase was considerable.
Teladoc rises on increased demand, should you buy this high risk play?
Teladoc health's services witness an increase in demand according to the latest web traffic figures, as per Jeffries analysts.
Why Teladoc (TDOC) Outpaced the Stock Market Today
Teladoc (TDOC) closed at $8.16 in the latest trading session, marking a +0.87% move from the prior day.
Why Teladoc (TDOC) Outpaced the Stock Market Today
Teladoc (TDOC) closed at $7.25 in the latest trading session, marking a +0.83% move from the prior day.
Teladoc Stock Near 52-Week Low: Is it Healthy Enough to Invest?
TDOC is well positioned to grow in the long run on the back of expanding product offerings, memberships, AI integration, business diversification and global expansions.
Here's Why Teladoc (TDOC) Gained But Lagged the Market Today
In the closing of the recent trading day, Teladoc (TDOC) stood at $7.17, denoting a +0.99% change from the preceding trading day.
Teladoc Health's New CEO Emphasizes Potential for Improvement Amid Mixed Results
Teladoc Health boasts substantial strengths and is positioned for enhanced performance, but according to new CEO Chuck Divita, there is work to do.
Is There Any Hope for Teladoc Stock?
Teladoc's second-quarter financial results disappointed investors. The telemedicine company still has several things going its way.
3 Telemedicine Stocks Poised for Possible Healthcare Evolution
Telemedicine stocks could do no wrong during the pandemic. With millions on lockdown and still in need of medical care, telemedicine stocks, like Teledoc Health (NYSE:TDOC) ranfrom about $80 to a high of $288.80.
Teladoc: Falling Knife Status Or Kitchen Sink Guidance?
Teladoc's new management has delivered a painful FQ2'24 earnings call, as observed in the BetterHelp impairment costs and withdrawn forward guidance. It is apparent that the telehealth company is facing growth issues and elevated marketing/advertising costs, with its near-term prospects likely to remain underwhelming. Readers must note the upcoming Livongo notes are likely to trigger further equity dilution, worsening the highly shorted stock's ongoing insider selling.
